Large Desmoid Tumor of the Pancreas: A Report of a Rare Case and Review of the Literature.

BACKGROUND Desmoid tumor (DT), also known as aggressive fibromatosis or desmoid-type fibromatosis, is a rare disease. It can occur in anyone at any age, and is more likely to appear in female patients. DTs are sometimes associated with familial adenomatous polyposis and rare syndromes such as Gardner syndrome. Arising from specific cells, fibroblasts, they tend to develop in patients with a history of abdominal surgery and rarely produce metastases. CASE REPORT We present a case of a 41-year-old man who was referred for abdominal discomfort with no digestive or general symptoms. An abdominal CT scan revealed a mass in the left hypochondrium, corresponding to an intraperitoneal tumor extending to left colon. Based on MRI, we suspected a gastrointestinal stromal tumor. Colonoscopy showed no intraluminal tumor in the colon. A PET-CT scan revealed tumor hypermetabolism and no metastases. The mass was diagnosed as a DT after percutaneous biopsy. Six weeks after diagnosis and as the tumor continued increasing despite pharmacological treatment, the patient underwent surgical pancreatic tail resection with splenectomy and left colonic segmentectomy. Histological examination revealed a 7.047-g DT with severe infiltration of pancreatic parenchyma and transmural colic barrier, with no high-grade differentiation and negative resection margins. The postoperative recovery was uneventful, and we proposed surveillance with MRI. CONCLUSIONS The DT was surgically removed and patient remains under MRI surveillance. Other reported management approaches consist of radiotherapy, tyrosine kinase inhibitors, anti-hormonal therapies/non-steroidal anti-inflammatory drugs, chemotherapy, or close surveillance only. This is, to our knowledge, the largest and heaviest DT reported in the modern literature.

[The care of the sexuality among oncologic patients - A research project within the University hospitals of Geneva]. / Prise en charge de la sexualité chez les patients oncologiques: Un projet de recherche au sein des Hôpitaux universitaires de Genève.

Cancer affects sexual function, sexual health and relationships as well as mental health and quality of life. Due to the importance of sexual health for each individual and in order to ensure optimal and quality care, we have assessed the demand for sexual health and advise not only among cancer patients but also among professionals in this area and nursing staff. The results showed that sexuality was important both for patients and caregivers. Also we did find out that carers want to create a better professional network with the aim of redirecting patients to specialists according to their specific needs. Carers have also expressed a desire to have relevant training in sexology and sexual health to achieve this.

Les cancers affectent la fonction sexuelle, la santé sexuelle, la relation de couple, ainsi que la santé mentale et la qualité de vie. Pour assurer une prise en charge et une qualité de soins optimales, en raison de l'importance de la santé sexuelle pour chaque individu, nous avons évalué la demande concernant la sexualité et la santé sexuelle chez les patients atteints d'un cancer et les besoins de connaissances professionnelles dans ce domaine du personnel soignant. Les résultats ont montré que la sexualité avait une place importante chez les patients et les soignants. De plus, les soignants souhaitent créer un meilleur réseau professionnel, dans le but de rediriger les patients vers des spécialistes, en fonction de leurs besoins spécifiques. Enfin les soignants ont exprimé une volonté de mieux se former en sexologie et en santé sexuelle.

[Cancer and sexual medicine: a hand to the human]. / Médecine sexuelle et cancers : une main tendue vers l'humain.

Cancer itself and its treatments can result in physical and/or psychological adverse events which include disorders of sexual health. Both clinicians and patients are reluctant to talk about sexual issues, body image or intimacy between partners. Barriers from the clinician's perspective include feeling inadequately trained, lack of time or privacy. On the patients' side, embarrassment or belief that their sexual health are an untreatable complication of their disease and its treatment are the main barriers. Concerned by this problematic, a multidisciplinary group was created to address the question of sexual health in cancer patients and to set up a specialized training for the clinicians, with the overall goal to integrate this field in the standard management of cancer patients.

Le cancer et ses traitements peuvent induire de nombreux effets secondaires. Parmi eux, les problèmes liés à la santé sexuelle sont souvent laissés de côté, tant par les cliniciens que par les patients eux-mêmes. Du côté des cliniciens, les principaux obstacles évoqués sont le sentiment d'une formation inadéquate, ou le manque de temps ou d'intimité. Du côté des patients, la gêne ou l'impression que les problèmes sexuels liés au cancer sont incurables, sont souvent retrouvées. Devant cette problématique, un groupe multidisciplinaire a été créé pour traiter de la santé sexuelle des patients oncologiques et mettre en place une formation spécialisée pour les cliniciens, avec comme objectif global d'intégrer la problématique sexuelle dans la prise en charge globale de ces patients.

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer.

Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer progressing on standard therapies. Here, we describe the clinical history of a 63-year-old male patient who was treated with regorafenib in the pivotal CORRECT trial. The patient was initially diagnosed in November 2008 with nonmetastatic KRAS-mutated (exon 2, codon 12) rectal cancer. He underwent successful surgery and was treated with 5 cycles of adjuvant chemotherapy. In 2010, lung metastases (KRAS-mutated) were detected and the patient received 6 cycles of FOLFIRI plus bevacizumab. By January 2011, the metastases had progressed. The patient, who was asymptomatic with an Eastern Cooperative Oncology Group performance status of 0, was enrolled onto the CORRECT trial and received best supportive care plus regorafenib (160 mg once daily for 3 weeks of a 4-week cycle) over a period of 2 years, during which time the disease remained stable and the patient remained asymptomatic. Grade 1 anemia and thrombocytopenia were the only treatment-emergent adverse events reported. After receiving 26 cycles of regorafenib, a majority of the lung lesions progressed, and third-line palliative 5-fluorouracil, leucovorin, and oxaliplatin chemotherapy was administered. The patient died in May 2016.

[Management of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy]. / Prise en charge de la carcinose péritonéale par chirurgie cytoréductive et chimiothérapie hyperthermique intrapéritonéale.

In 2016, peritoneal carcinomatosis can be considered as a chronic disease that can be treated and sometimes cured. Hyperthermic Intra PEritoneal Chemotherapy (HIPEC) is a procedure developed in the eighties. Combined with CytoReductive (CR) surgery, this protocol underwent a considerable expansion in Washington Cancer Institute. CR combined with HIPEC was demonstrated to be the only curative treatment for PseudoMyxoma Peritonei syndrome (PMP). It is actually approved in the management of peritoneal carcinomatosis of ovarian, colorectal, or peritoneal primitive (mesothelioma) origin but is still studied for gastric cancer. CR/HIPEC is associated with an important mortality and morbidity. This article takes stock of indications to CR/HIPEC.

[Opening of the Geneva University Hospital Prostate Cancer Center]. / Création du Centre du cancer de la prostate des HUG.

In 2014, Geneva University Hospital has opened the first certified prostate cancer Center of western Switzerland. It incorporates 29 entities implicated in the diagnosis and treatment of this disease, thereby assuring that all available ressources are made available to patients, regardless of the division to which they were initially referred. The main strength of the Center lies in the synergy generated by its multidisciplinary tumor board. Furthermore, regular conferences, staff meetings, propectively held registers and the yearly re-certification audit support its constant quality improvement.

[Exemples of tumor markers and their clinical utility]. / Marqueurs tumoraux: quelle utilité en pratique clinique?

The burden of the decisions related to cancer management is the reason why doctors are trying to use the best indicators to manage doubt and uncertainty, as well as to improve treatment targeting. These indicators are called tumor markers. They may assist in the diagnostic process and help in establishing the prognosis. They may be used for screening an asymptomatic disease, early detection of recurrent disease and mainly follow-up during cancer therapies. The better understanding of carcinogenesis coupled to technical improvements led to the discovery of new markers. They target cellular or genetic abnormalities and revisit classic cancer classification while some predict disease response to targeted therapies. This is the era of personalized oncology.